With approximately a third of US adults classified as obese or overweight and 26% expressing a desire to lose weight, we could see a considerable decrease in calorie intake if 10% of US adults use these drugs within the next five years
Appetite suppressionwhich is actually the intended therapeutic effectbecomes increasingly pronounced as the week progresses
For those uninsured or whose insurance doesnt cover it, the coupon caps the price at $199 per month
[Abstract]2024 Jun 21;20(6):e1012305
The STRIVE study is an open-label, real-world randomized control trial assessing the financial burden and practical implications of daily liraglutide administration to patients with obesity, prediabetes, T2D, hypertension, and/or OSA (Papamargaritis et al., 2020)
Wang X, Chen Y, Wang X, Tian H, Wang Y, Jin J, et al